Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients.


Journal

International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 31 08 2021
accepted: 18 11 2021
pubmed: 25 11 2021
medline: 25 2 2022
entrez: 24 11 2021
Statut: ppublish

Résumé

To compare clinical outcome and quality of life (QoL) in octogenarian patients with muscle-invasive urothelial carcinoma (MIBC) either treated by radical cystectomy (RC) or transurethral resection of the tumor (TURBT). We identified octogenarian patients with MIBC in our institutions since 2005. Clinical treatment outcomes and QoL were analyzed. Uni- and multivariable Cox regression analyses, two-tailed Wilcoxon test, Mann-Whitney test and Fisher's exact test were assessed as appropriate. QoL was evaluated using FACT-G (Functional Assessment of Cancer Therapy-General) questionnaire. 143 patients were identified (RC: 51 cases, TURBT: 92 cases). Mean follow-up was 14 months (0-100 months). Median overall survival (OS) was 12 months in the RC group and 7 months in the TURBT group. TURBT and low preoperative hemoglobin were independent risk factors for reduced cancer-specific survival (CSS) (TURBT: p = 0.019, Hb: p = 0.008) and OS (TURBT: p = 0.026, Hb: p = 0.013) in multivariable analyses. Baseline QoL was low throughout the whole cohort. There was no difference in baseline FACT-G scoring comparing RC and TURBT (FACT-G total score (median): RC 43.7/108 vs. TURBT 44.0/108, p = 0.7144). Increased FACT-G questionnaire scoring was assessed for RC patients (median percentage score change RC 22.9%, TURBT 2.3%, p < 0.0001). RC and TURBT are feasible treatment options for MIBC in octogenarian patients. In our cohort, RC was associated with increased CSS, OS and QoL. QoL in general was low throughout the whole cohort. Interdisciplinary decision-making has to be improved for these critically ill patients.

Identifiants

pubmed: 34817753
doi: 10.1007/s11255-021-03073-5
pii: 10.1007/s11255-021-03073-5
pmc: PMC8732805
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

71-79

Informations de copyright

© 2021. The Author(s).

Références

Urology. 2004 Aug;64(2):292-7
pubmed: 15302481
Br J Cancer. 2013 Apr 16;108(7):1534-40
pubmed: 23481180
Indian J Urol. 2016 Oct-Dec;32(4):282-287
pubmed: 27843210
J Urol. 2011 Sep;186(3):829-34
pubmed: 21788035
Tumori. 2018 Aug;104(4):252-257
pubmed: 28967093
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Health Qual Life Outcomes. 2003 Dec 16;1:79
pubmed: 14678568
Indian J Urol. 2016 Jul-Sep;32(3):232-7
pubmed: 27555684
Eur Urol. 2009 Sep;56(3):443-54
pubmed: 19481861
Cancer. 2006 Jun 1;106(11):2355-62
pubmed: 16649218
Nat Clin Pract Urol. 2009 Mar;6(3):135-44
pubmed: 19265855
J Urol. 2001 Sep;166(3):938-41
pubmed: 11490250
Urol Oncol. 2004 May-Jun;22(3):178-81
pubmed: 15271311
Urology. 2008 May;71(5):919-23
pubmed: 18355900
J Urol. 2002 Mar;167(3):1325-8
pubmed: 11832724
J Clin Oncol. 2001 Feb 1;19(3):666-75
pubmed: 11157016
Can J Urol. 2016 Apr;23(2):8198-203
pubmed: 27085823
Urol Oncol. 2009 Nov-Dec;27(6):653-67
pubmed: 19879476
BMC Urol. 2020 Mar 19;20(1):31
pubmed: 32192483
BJU Int. 2011 Aug;108(4):539-45
pubmed: 21166753
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Eur Urol. 2014 Apr;65(4):778-92
pubmed: 24373477
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325
Eur Urol. 2004 Feb;45(2):147-53; discussion 154
pubmed: 14733998
Investig Clin Urol. 2016 Jun;57 Suppl 1:S26-35
pubmed: 27326404
Int Braz J Urol. 2013 Sep-Oct;39(5):622-30
pubmed: 24267105
Aging Male. 2020 Sep;23(3):210-215
pubmed: 31621489
Cancer. 2005 Jul 1;104(1):36-43
pubmed: 15912515
J Urol. 2007 Apr;177(4):1287-93
pubmed: 17382715
Eur Urol. 2007 Mar;51(3):699-706; discussion 706-8
pubmed: 17113703
Urologia. 2019 Nov;86(4):183-188
pubmed: 31364495
Support Care Cancer. 2019 Nov;27(11):4189-4198
pubmed: 30825026

Auteurs

Christian Rehme (C)

Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany.

Beatrix Fritsch (B)

Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany.

Luca Thomas (L)

Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany.

Stefan Istin (S)

Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany.

Carolin Burchert (C)

Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany.

Bastian Hummel (B)

Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany.

Bogdan Baleanu-Curaj (B)

Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany.

Henning Reis (H)

Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany.

Tibor Szarvas (T)

Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany.
Department of Urology, Semmelweis University, Budapest, Hungary.

Herbert Ruebben (H)

Department of Urology, Helios Hospital Duisburg, Duisburg, Germany.

Boris Hadaschik (B)

Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany.

Christian Niedworok (C)

Department of Urology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 52, 45147, Essen, Germany. christian.niedworok@uni-due.de.
Department of Urology, Hermann-Josef-Hospital, Erkelenz, Germany. christian.niedworok@uni-due.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH